Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study ; volume:21 ; number:1 ; day:8 ; month:11 ; year:2019 ; pages:1-9 ; date:12.2019
Arthritis Research & Therapy ; 21, Heft 1 (8.11.2019), 1-9, 12.2019
- Creator
-
Simon, Teresa A.
Boers, Maarten
Hochberg, Marc
Baker, Nicole
Skovron, Mary L.
Ray, Nitesh
Singhal, Sanket
Suissa, Samy
Gomez-Caminero, Andres
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-019-1992-x
- URN
-
urn:nbn:de:101:1-2020030619540800340277
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simon, Teresa A.
- Boers, Maarten
- Hochberg, Marc
- Baker, Nicole
- Skovron, Mary L.
- Ray, Nitesh
- Singhal, Sanket
- Suissa, Samy
- Gomez-Caminero, Andres
- SpringerLink (Online service)
Other Objects (12)
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
Real-world retention rates of biologics in patients with rheumatoid arthritis
Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Biologics in therapy
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen
Initiating learning
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
Real-world retention rates of biologics in patients with rheumatoid arthritis
Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Biologics in therapy
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen
Initiating learning
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
Real-world retention rates of biologics in patients with rheumatoid arthritis
Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Biologics in therapy
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen